Brokerages Set Spruce Biosciences, Inc. (NASDAQ:SPRB) Target Price at $176.38

Spruce Biosciences, Inc. (NASDAQ:SPRB) has been given a consensus rating of “Hold” by the ten research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $176.3750.

Several research analysts recently weighed in on the company. Citizens Jmp upgraded Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $254.00 price objective for the company in a research report on Tuesday. Leerink Partners set a $160.00 price objective on Spruce Biosciences and gave the stock a “market perform” rating in a research report on Tuesday, October 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Spruce Biosciences in a research note on Tuesday, October 14th. Zacks Research cut Spruce Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 23rd. Finally, JMP Securities set a $254.00 price target on Spruce Biosciences and gave the stock a “market outperform” rating in a research note on Tuesday.

Spruce Biosciences Stock Performance

Shares of Spruce Biosciences stock opened at $107.25 on Tuesday. The firm has a market capitalization of $60.06 million, a price-to-earnings ratio of -1.24 and a beta of 2.47. Spruce Biosciences has a fifty-two week low of $4.28 and a fifty-two week high of $240.00. The stock has a 50 day moving average of $61.03 and a 200 day moving average of $26.04.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.